Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management there is broadly based on three types of treatments—conventiontal disease-modifying antirheumatic drugs (cDMARDs) (e.g., methotrexate, leflunomide); biological DMARDs (tumor necrosis factor-alpha [TNF-α] inhibitors, an anti-CD20 monoclonal antibody, an interleukin-6 inhibitor, and a selective co-stimulation inhibitor); and Janus-activated kinase (JAK) inhibitors (tofacitinib and baricitinib). The TNF-α inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs; the other biologics and JAK inhibitors largely compete for use in TNF-α inhibitor-refractory patients. The approval of cost-effective biosimilars and incorporation of several therapies into China’s National Reimbursement Drug List will lead to improved access for patients. With the expected launch of additional targeted therapies during the forecast period, the Chinese RA therapy market will witness robust growth.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with rheumatologists in China.
Epidemiology: Diagnosed prevalence of RA in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient shares of key RA therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 8 drugs; Phase II: 4 drugs; coverage of select preclinical and Phase I products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.